Neurologist Says Severe Headaches Can Be Long-Lasting COVID-19 Symptom – News On 6

A neurologist said theres another long-lasting symptom of COVID-19: severe headaches.

Dr. Jaclyn Duvall said post-viral headaches are nothing new, but whats different about COVID is how long the headaches last and how intense they can be. Dr. Duvall said without treatment, these headaches can be crippling.

"This can be completely life-changing," Duvall said.

Amber Ostasik is one of Dr. Duvall's patients at Hillcrest's Utica Park Clinic. She suffered severe headaches for months after her COVID-19 diagnosis.

"It was very debilitating," Ostasik said. "I was in and out of urgent care because the pain would get so bad that I didn't know what to do."

Ostasik said she was diagnosed with COVID-19 last June and after a few weeks of recovery thought she was in the clear, but the headaches came back.

"When they came back, they came back with a vengeance. Headaches, that doesnt sum up what I was having. I was having head pain. I mean I couldnt see straight the pain was so bad.By the time I saw Dr. Duvall I was in a desperate place," Ostasik said.

Dr. Duvall said the majority of people with the coronavirus won't experience such serious symptoms, but a growing number of people aren't so fortunate.

"I'd say a vast majority of individuals are actually improving within the first few weeks after recovery, but we are seeing a number of patients that are having these lingering effects, even in Amber's case up to 100 days after experiencing COVID," Dr. Duvall said.

Ostasik recovered after specialized treatment but said when she was first diagnosed with COVID-19, she never expected such severe symptoms to last so long.

"I'm in my mid-thirties, I run marathons, I'll be fine. If I get it, I'll get over it within two weeks," Ostasik thought. "I think it was really eye-opening not just for me, but for everyone around me. This could be potentially life-changing."

Dr. Duvall said if your symptoms also linger well after a COVID diagnosis, you should consider going to a specialist for treatment.

Excerpt from:
Neurologist Says Severe Headaches Can Be Long-Lasting COVID-19 Symptom - News On 6

Once bitten, twice shy: the neurology of why one bad curry could put us off for life – Newswise

Newswise A negative experience with food usually leaves us unable to stomach the thought of eating that particular dish again. Using sugar-loving snails as models, researchers at the University of Sussex believe these bad experiences could be causing a switch in our brains, which impacts our future eating habits.

Like many other animals, snails like sugar and usually start feeding on it as soon as it is presented to them. But through aversive training which involved tapping the snails gently on the head when sugar appeared, the snails' behaviour was altered and they refused to feed on the sugar, even when hungry.

When the team of Sussex Neuroscience researchers led by Dr Ildiko Kemenes looked a little closer, they discovered a neuronal mechanism that effectively reversed the snails' usual response to sugar after the conditioning training had taken place.

Dr Ildiko Kemenes, Reader in Neuroscience in the University of Sussex's School of Life Sciences, explained: "There's a neuron in the snail's brain which normally suppresses the feeding circuit. This is important, as the network is prone to becoming spontaneously activated, even in the absence of any food. By suppressing the feeding circuit, it ensures that the snail doesn't just eat everything and anything. But when sugar or other food stimulus is present, this neuron becomes inhibited so that feeding can commence.

"After the aversive training, we found that this neuron reverses its electrical response to sugar and becomes excited instead of inhibited by it. Effectively, a switch has been flipped in the brain which means the snail no longer eats the sugar when presented with it, because sugar now suppresses rather than activates feeding."

When researchers presented the trained snails with a piece of cucumber instead, they found that the animal was still happy to eat the healthy option - showing that the taps were associated with only the particular type of food they were trained to reject.

George Kemenes, Professor of Neuroscience at the University of Sussex and a senior member of the investigator team, added: "Snails provide us with a similar yet exceptionally basic model of how human brains work.

"The effect of the inhibitory neuron which suppresses the feeding circuit in the snail is quite similar to how, in the human brain, cortical networks are under inhibitory control to avoid 'runaway' activation which may lead to overeating resulting in obesity.

"In our research, the negative experience the snail had with the sugar could be likened to eating a bad takeaway curry which then puts us off that particular dish in future.

"We believe that in a human brain, a similar switch could be happening where particular groups of neurons reverse their activity in line with the negative association of a particular food. "

The research, funded by the Biotechnology and Biological Sciences Research Council (BBSRC) and published inCurrent Biology, also revealed that when the neuron was removed entirely from trained snails, they returned to eating sugar again.

Dr Ildiko Kemenes said: "This suggests that the neuron is necessary for the expression of the learned behaviour and for altering the response to sugar.

"However, we cannot rule out that the sugar-activated sensory pathway also undergoes some changes, so we don't make the assumption that this is all that's happening in the brain."

###

Visit link:
Once bitten, twice shy: the neurology of why one bad curry could put us off for life - Newswise

Ocala neurologist to pay $800K to settle allegations of prescribing unnecessary drugs – Ocala

A lawsuit filed against the Florida Neurological Center, LLC and its owner, Dr. Lance Kim of Ocala, in which the defendants were accused of several fraudulent practices under the False Claims Act, has been partially settled.

Kim and the Florida Neurological Center (FNC), located at 2237 SW 19th Ave. Road, Suite 101, have agreed to pay $800,000 to resolve allegations that Kim prescribed medically unnecessary and unreasonable prescription drugs, according to a press release from the U.S. Attorneys Office for the Middle District of Florida.

The release specifically noted Acthar Gel, a prescription drug that cost the Medicare program around $35,000 for every five-day supply Kim prescribed.

$65 million expansion: Ocala Regional Medical Center celebrates groundbreaking of neuro ICU, CV suites

COVID-19 spike: Marion County's 7-day positivity rate now above 19 percent, CDC says

Things you didn't know about WEC: Secret garden, saddle stools, Journey's keyboardist

The agreement partially resolves the allegations brought against Kim and the center, andthere has been no determination of liability.

The lawsuit was filed in Orlando by Michael Singbush, Andrea Herrera and Harvey Kessler MeyerIV, all former employees of the Florida Neurological Center between 2014 and 2017. Under the False Claims Act, private individuals, or relators, can sue, on behalf of the government, companies and individuals that they believe to be defrauding government programs.

Also under the act, the relators are permitted to receive a share of the recovery, totaling $144,000 in this case.

Florida Attorney General Ashley Moodys office issued a press release on the settlement Tuesday, stating that she is working with federal partners to recover thousands of dollars for Floridas Medicaid program related to the settlement.

The program will receive over $113,000 in restitution from the agreement.

Defrauding Floridas Medicaid program is not a victimless crime, Moody said in the release. It harms the taxpayers of our great state. My Medicaid Fraud Control Unit investigators work hard to protect taxpayers by identifying, investigating and stopping fraud exploiting this taxpayer-funded health care program and recovering lost funds whenever possible.

FNC has served Marion County since 1998, according to its website. It specializes in evaluating and treating neurological disorders such as Alzheimers disease, neuropathy, muscle disorders and sleep disorders.

Kim received his undergraduate degree in biochemistry from Boston University and medical degree from Nova Southeastern University in Fort Lauderdale.

He has worked as a research fellow at the Harvard Medical School/Massachusetts General Hospital, interned in internal medicine at Northwestern University Medical Center and received a residency and fellowship in neurology from the University of Chicago.

Kim is the owner and sole practicing physician of FNC.

In a pretrial statement from May, the plaintiffs had maintained that Kim and FNC violated the False Claims Act (FCA) and that each plaintiff faced retaliation after complaining of the illegal actions.

The relators explained that the basic requirement for reimbursement from Medicare, Medicaid and other government healthcare programs is that services are reasonable and medically necessary. They described various ways in which they believed FNC submitted false claims.

The defendants denied any wrongdoing under the FCA, and the parties agreed to a voluntary dismissal of most of the counts on Tuesday.

The claimsthat each relator faced retaliation for questioning the practices and was either forced to resign or fired are still pending.

FNC and Kim deny any retaliation or that the relators engaged in protected activity, which prevents whistleblowers from retaliation.

FNC also soughtdamagein a counterclaim against Singbush, Herrera and Meyer, alleging unlawful use and disclosure of confidential information about patients, as well as breach of employment agreements. Those claims were dismissed in June.

The U.S. Attorneys Office for the Middle District of Florida reminds that tips about potential fraud, waste, abuse and mismanagement can be reported to the Department of Health and Human Services at 800-HHS-TIPS (800-447-8477).

Contact reporter Danielle Johnson at djohnson@gannett.com.

Read the rest here:
Ocala neurologist to pay $800K to settle allegations of prescribing unnecessary drugs - Ocala

A plea for equitable global access to COVID-19 diagnostics, vaccination and therapy: the NeuroCOVID-19 task Force of the european Academy of neurology…

This article was originally published here

Eur J Neurol. 2021 Jan 18. doi: 10.1111/ene.14741. Online ahead of print.

ABSTRACT

Coronavirus disease 2019 (COVID-19), a multi-organ disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to challenge health and care systems around the globe. The pandemic has disrupted acute neurology services and routine patient care and has impacted the clinical course in patients with chronic neurologic disease. COVID-19 appears to have exposed inequalities of societies and healthcare systems and had disproportionate impact on already vulnerable communities. The next challenge will be to set up initiatives to stop disparities in all aspects related to COVID-19. From the medical perspective, there is a need to consider inequalities in prevention, treatment, and long-term consequences. Some of the issues of direct relevance to neurologists are summarised. With this appraisal, the European Academy of Neurology NeuroCOVID-19 Task Force intends to raise awareness of the potential impact of COVID-19 on inequalities in healthcare and calls for action to prevent disparity at individual, national and supranational level.

PMID:33460486 | DOI:10.1111/ene.14741

Read more here:
A plea for equitable global access to COVID-19 diagnostics, vaccination and therapy: the NeuroCOVID-19 task Force of the european Academy of neurology...

Examining the neurological manifestations of COVID-19 – Contemporary Pediatrics

An investigation looks at the neurological manifestations of COVID-19.

Although coronavirus disease 2019 (COVID-19) is first and foremost a respiratory disease, the past year has shown that the disease can also impact other systems in the body, particularly the cardiovascular system. A report in TheLancet Children & Adolescent Health looks at how the disease shows up in neuroimaging.1

The researchers put out an international call to find cases of children who had encephalopathy that was linked to a severe case of COVID-19. They asked for the clinical history as well as association cerebrospinal fluid and plasma data for each case as well. Each case was looked at by a child neurologist, pediatric infectious disease expert, and central neuroradiology panel. Any case that did not have a direct link to a COVID-19 infection was excluded from the study.

A total of 38 children with neurological disease linked to COVID-19 were found in France, the United Kingdom, the United States, Brazil, Argentina, India, Peru, and Saudi Arabia. The researchers found recurring patterns of disease and the neuroimaging abnormalities seen ranged from mild to severe. The most common neuroimaging patterns found were postinfectious immune-mediated acute disseminated encephalomyelitis-like changes of the brain (16 patients), neural enhancement (13 patients), and myelitis (8 patients). Children with multisystem inflammatory syndrome in children were the ones most likely to have splenial lesions (7 patients) and myositis (4 patients). Complications in the cerebrovascular system were not as common among children and adults. No significant pre-existing conditions were seen in children and most of them had favorable outcomes. Four children who previously been healthy before COVID-19 developed fatal atypical central nervous system co-infections.

The researchers concluded that central nervous system abnormalities have been seen in children who had COVID-19. They urged further research to get a better understanding of how the disease can impact the central nervous system as well as provide information on how to provide long-term follow-up care.

Reference

1. Lindan C, Mankad K, Ram D, et al. Neuroimaging manifestations in children with SARS-CoV-2 infection: a multinational, multicentre collaborative study. Lancet Child Adolesc Health. December 15, 2020. Epub ahead of print. doi:10.1016/S2352-4642(20)30362-X

Read more:
Examining the neurological manifestations of COVID-19 - Contemporary Pediatrics

Optic Nerve Data Helps Boost Diagnostic Performance Among Patients With MS – Neurology Advisor

Researchers from the Universitat Autnoma de Barcelona in Spain found that incorporating features of the optic nerve into multiple sclerosis (MS) diagnostic criteria improved diagnostic performance by increasing sensitivity without lowering specificity, according to study results published in Neurology.

Data for this study came from a prospective study of 1238 patients diagnosed with clinically isolated syndrome after a single magnetic resonance imaging (MRI) scan performed between 1995 and 2017. Study investigators retrospectively assessed data of visual evoked potentials through patient medical records. They split patients into risk assessment (n=388) and diagnostic criteria performance (n=151) cohorts to validate whether MS diagnostic criteria improved with the addition of optic nerve information.

At clinically isolated syndrome diagnosis, patients were a mean age of 31.6 (standard deviation [SD], 8.2 years). 68% of patients were women; 63.6% had nonoptic neuritis; 58.8% were positive for oligoclonal bands; 71.2% had an abnormal MRI; 37.8% had abnormal visual evoked potentials; and the median extended disability status scale was 1 (range, 0-5.5).

Among cohort 1, persons with higher levels of diagnostic criteria were at increased risk for a second attack from 1 criterion (hazard ratio [HR] 5.6; 95% CI, 1.9-16.5) to 5 criteria (HR 22.7; 95% CI, 7.9-65.7).

The 2017 dissemination in space (DIS) criteria identified a similar risk for second attack (HR, 4.3; 95% CI, 2.8-6.5) as the modified DIS (modDIS) (HR, 4.8; 95% CI, 3.0-7.5). Stratified by optic nerve involvement, the risk for a second attack was projected to be elevated among patients with optic neuritis using the modDIS (HR, 4.3; 95% CI, 1.9-9.6) compared with 2017 DIS (HR, 3.8; 95% CI, 1.8-8.0).

Among cohort 2, identifying the risk for second attack at 10 years according to the 2017 DIS was less precise (sensitivity, 79.2%; specificity, 52.4%; accuracy, 75.5%; positive predictive value [PPV], 91.1%; negative predictive value [NPV], 28.9%) compared with the modDIS (sensitivity, 82.3%; specificity, 52.4%; accuracy, 78.1%; PPV, 91.4%; NPV, 32.3%).

Similarly, among only the patients with optic neuritis, the 2017 DIS predicted a second attack at 10 years with a poorer overall performance (sensitivity, 69.7%; specificity, 57.1%; accuracy, 67.5%; PPV, 88.5%; NPV, 28.6%) compared with the modDIS criteria (sensitivity, 75.8%; specificity, 57.1%; accuracy, 72.5%; PPV, 89.3%; NPV, 33.3%).

This study may have included some selection bias, as researchers included only patients with complete medical records in the 2 cohorts analyzed here.

According to their findings, the study researchers concluded that the addition of the optic nerve to the current DIS criteria slightly increases the accuracy and sensitivity without lowering the specificity, providing additional evidence that argues in favor of including the optic nerve as a new region in the diagnostic criteria.

Disclosure: Multiple authors declared affiliations with industry. Please refer to the original article for a full list of authors disclosures.

Reference

Vidal-Jordana A, Rovira A, Arrambide G, et al. Optic nerve region in multiple sclerosis diagnosis: the utility of visual evoked potentials. Published online December 16, 2020. Neurology. doi:10.1212/WNL.0000000000011339

View original post here:
Optic Nerve Data Helps Boost Diagnostic Performance Among Patients With MS - Neurology Advisor

My wife has a degenerative neurological disease. My father-in-law wants to put her in a facility and take over our finances – MarketWatch

Dear Moneyist,

I have been married for 24 years. My wife and I have two 18-year-old children. We have had our marital ups and downs as many do, but manage to get along. My wife was diagnosed with a terminal degenerative neurological condition.

She grows increasingly frail, both physically and cognitively. Although at times it is not easy, myself and our two children, who are home from school due to the pandemic, care for her the best we can. She lives very comfortably in the home we have owned for 20 years.

The Moneyist:I took care of my late mother for 8 years. Am I obliged to tell my sisters she made me co-owner of a substantial bank account?

My wifes family is largely dysfunctional, and her father abandoned her as a young child, never returning in any meaningful way or providing support aside from cards and perfunctory holiday pleasantries. I do not get along with my father-in-law and have largely avoided him.

Upon learning of my wifes condition, my father-in-law now seems obsessed with moving my wife out of our home to some sort of group home/facility. The mere thought of this seems abhorrent and barbaric. My thinking is that he intends to obtain guardianship and access marital assets, mainly our home, which has substantial value and equity.

My greatest wish is to avoid a bitter legal fight in my wifes last years, and provide her with the best care, medical and otherwise.

Devoted Husband

Want to read more?Follow Quentin Fottrell on Twitterand read more of his columns here

Dear Devoted,

Tell your father-in-law that you have heard his opinion, but now you and your children need to take care of your wife at home together as a family, in your own way, and ask him to respect your wishes. If he continues, tell him that you understand that this is an uncertain and concerning time for all of you, but you would like him to trust you and your family to take care of your wife and his daughter. If that doesnt work, you can say, I now need time and space now to take care of things here. I hope you can give me that. You dont have to answer every call and email.

I also advise you to talk to your wife about officially becoming her health-care proxy, so you will be in control of making any life or death decisions concerning her condition. Alternatively, talk to a lawyer about this. Its smart to have a health-care proxy, no matter how old you are or whether or not youre married, according to Care.com. And a health-care proxy also allows you to designate an alternate, so if you and your spouse are in an accident together you still have control over whos making health-care decisions on your behalf.

Similarly, Leanna Hamill, a family attorney in Hingham, Mass., says, If your parents and spouse disagree about your care, this can cause real problems. The best thing to do is execute a health-care proxy appointing the person you choose as your health care agent and then talking to that person and your other family members about your wishes. (Lawyers want to avoid the kind of legal trauma surrounding the life and death of Terry Schiavo.) Regardless, doctors will turn to your wifes next of kin for any vital decisions that need to be made regarding her care. Thats you.

The Moneyist: My son inherited money after his father was killed in an accident. A woman came forward with another legal heir. What now?

But there is no reason to assume the same will happen here. You will feel less anxious about your father-in-laws interference when you speak up. You dont have to be held hostage to other peoples wishes. Lets assume he wants what he believes is best for his daughter. You simply have a different opinion and approach. He cant force you to sell your home or refinance your home to do something you dont want to do. You are probably under more stress than you realize, and his interference may be a proxy for that stress. It is, perhaps, an obvious if not exactly a useful place to put it.

In the meantime, I recommend seeking out counseling and/or support to help you through this difficult time. The Well Spouse Association is a nonprofit organization that has support groups in communities all over the country. Your wifes condition and comfort is, of course, your No. 1 priority. Dont allow other family members, friends or neighbors to distract you from that. You can only do so much. By creating a support network and healthy boundaries with others however well-meaning they may be I have no doubt that your commitment to your wifes care will be enough.

The Moneyist: My mothers husband died. Her savings are dwindling, yet she pays my sisters bills. Should I intervene?

You can email The Moneyist with any financial and ethical questions related to coronavirus at qfottrell@marketwatch.com

Would you like to sign up to an email alert when a new Moneyist column has been published? If so, click on this link.

Hello there, MarketWatchers. Check out the Moneyist private Facebook FB, +3.87% group where we look for answers to lifes thorniest money issues. Readers write in to me with all sorts of dilemmas. Post your questions, tell me what you want to know more about, or weigh in on the latest Moneyist columns.

Follow this link:
My wife has a degenerative neurological disease. My father-in-law wants to put her in a facility and take over our finances - MarketWatch

Neurologic Disorders Therapeutics Market Size, Trends, Growth, Scope, Overall Analysis and Forecast by 2027 – The Haitian-Caribbean News Network

New Jersey, United States: Market Research Intellect has added a new report to its huge database of research reports, entitled Neurologic Disorders Therapeutics Market Size and Forecast to 2027. The report offers a comprehensive assessment of the market including insights, historical data, facts, and industry-validated market data. It also covers the projections using appropriate approximations and methods.

Neurologic Disorders Therapeutics Market Overview

The Neurologic Disorders Therapeutics Market Report provides comprehensive data on market dynamics, market trends, product growth rate, and price. The Neurologic Disorders Therapeutics market report has various facts and statistics assuming the future predictions of the upcoming market participants. In addition, it offers business security taking into account sales, profit, market volume, demand and market supply ratio. The in-depth study provides vital information related to market growth, driving factors, major challenges, opportunities, and threats that will prove to be very helpful for market participants in making upcoming decisions.

Neurologic Disorders Therapeutics Market: Competitive Landscape

The Neurologic Disorders Therapeutics Market report consists of the Competitive Landscape section which provides a complete and in-depth analysis of current market trends, changing technologies, and enhancements that are of value to companies competing in the market. The report provides an overview of sales, demand, futuristic costs and data supply as well as a growth analysis in the forecast year. The key vendors in the market that are performing the analysis are also clearly presented in the report. Their development plans, their growth approaches, and their merger and acquisition plans are also identified. Information specific to a keyword in each of these regions is also provided. This report also discusses the submarkets of these regions and their growth prospects.

Prominent players operating in the market:

Neurologic Disorders Therapeutics Market Segmentation

The report contains the market size with 2019 as the base year and an annual forecast up to 2027 in terms of sales (in million USD). For the forecast period mentioned above, estimates for all segments including type and application have been presented on a regional basis. We implemented a combination of top-down and bottom-up approaches to market size and analyzed key regional markets, dynamics and trends for different applications.

Neurologic Disorders Therapeutics Market Segment by Type:

Neurologic Disorders Therapeutics Market Segment by Application:

Neurologic Disorders Therapeutics Market Regional overview:

In the report, experts analyze and forecast the Neurologic Disorders Therapeutics market on a global as well as regional level. Taking into account all aspects of the market in terms of regions, the focus of the report is on North America, Europe, Asia Pacific, the Middle East and Africa, and South America. The prevailing trends and various opportunities in these regions are studied that can convince the growth of the market in the forecast period 2020 to 2027.

Reasons to Buy the Neurologic Disorders Therapeutics Market Report:

Outlook analysis of the Neurologic Disorders Therapeutics market sector with current trends and SWOT analysis. This study evaluates the dynamics, competition, industrial strategies and strategies of the emerging countries. This report has a comprehensive guide that provides market insights and detailed data on each market segment Market growth factors and risks are presented. More precise information provision on the Neurologic Disorders Therapeutics market for different countries. Provide visions on factors influencing the growth of the market. Market segmentation analysis, including quantitative and qualitative research considering the impact of economic and non-economic aspects Comprehensive company profiles with product offerings, important financial information and the latest developments.

If you have any custom requirements, please let us know and we will offer you the customized report as per your requirements.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Website https://www.marketresearchintellect.com/

Read more:
Neurologic Disorders Therapeutics Market Size, Trends, Growth, Scope, Overall Analysis and Forecast by 2027 - The Haitian-Caribbean News Network

Study: Zika virus solution may lie in commonly used, tetracycline-based antibiotics – Homeland Preparedness News

Shutterstock

A preclinical study from the National Institutes of Health (NIH) suggests that tetracycline-based antibiotics like methacycline, or drugs designed to combat Alzheimers and inflammation, may slow infection and reduce neurological problems associated with the Zika virus.

This conclusion was based on use in mice after tests of more than 10,000 compounds. Researchers looked for drugs that would prevent Zika from reproducing by blocking the work of a protein known as NS2B-NS3 Zika virus protease. The protease releases proteins from RNA-injected cells that have been co-opted to produce more. By blocking these internal scissors, as study leader Dr. Rachel Abrams dubbed them, viruses like Zika can be counteracted.

Around the world, the Zika outbreak produced devastating, long-term neurological problems for many children and their families, said Dr. Avindra Nath, a senior investigator at the NIHs National Institute of Neurological Disorders and Stroke (NINDS) and a senior author of the study. Although the infections are down, the threat remains. We hope these promising results are a good first step to preparing the world for combating the next potential outbreak.

Zika is a primarily mosquito-spread virus that had its heyday in 2015 and 2016. It caused neurological disorders in adults and a developmental brain disorder in babies born from infected mothers. The virus prefers to attack stem cells in the brain.

In all, three drugs identified in this study may counteract the problems: methacycline, MK-591, or JNJ-404. Identifying these was achieved by feeding screening results into a computer and then using AI-based programs to assess what compounds would be good at blocking the protease activity. Tetracycline-based drugs are already approved by the U.S. Food and Drug Administration and are known to cross the placenta of pregnant women.

The antibiotics were not capable of fully counteracting the damage caused by Zika. Infected mice still had a lower weight than their control counterparts, whether treated with methacycline or not.

These results suggest that tetracycline-based antibiotics may at least be effective at preventing the neurological problems associated with Zika virus infections, Abrams said. Given that they are widely used, we hope that we can rapidly test their potential in clinical trials.

See the original post here:
Study: Zika virus solution may lie in commonly used, tetracycline-based antibiotics - Homeland Preparedness News

Diabetes, High Blood Pressure Raise Odds of COVID Harming Brain – HealthDay News

MONDAY, Nov. 30, 2020 (HealthDay News) -- COVID-19 patients with high blood pressure or diabetes may be more likely to develop critical neurological complications, including bleeding in the brain and stroke, according to an ongoing study.

University of Pennsylvania researchers studied COVID-19 patients who had a head CT scan or MRI within their health system between January and April 2020. In all, 81 of the 1,357 COVID-19 patients had a brain scan, usually because they had an altered mental state or speech and vision problems.

"COVID-19's effects extend far beyond the chest," said study lead author Dr. Colbey Freeman. He is chief resident in the department of radiology at Penn Medicine. "While complications in the brain are rare, they are an increasingly reported and potentially devastating consequence of COVID-19 infection," Freeman said.

Of the 81 patients, 18 (more than 20%) had critical or emergency brain issues, the scans revealed. At least half had histories of high blood pressure or type 2 diabetes. Three of the patients died in the hospital. Two-thirds of the patients with critical results were Black, according to the report.

"COVID-19 is associated with neurologic manifestations, and hypertension and type 2 diabetes mellitus are common in individuals who develop these manifestations," Freeman said in a news release from the Radiological Society of North America (RSNA). "These populations may be at higher risk for neurologic complications and should be monitored closely."

It is possible that inflammation is the reason for the observed neurological effects, the researchers said. Blood markers of inflammation were high in people with critical results.

"When your body is in an inflammatory state, it produces all these molecules called cytokines to help recruit the immune system to perform its function," Freeman explained. "Unfortunately, if cytokines are overproduced, the immune response actually starts doing damage."

The findings are scheduled for presentation at the RSNA's annual meeting, which is being held online Nov. 29 to Dec. 5. Research presented at meetings should be considered preliminary until published in a peer-reviewed journal.

The researchers are also investigating neurologic complications experienced by COVID-19 patients on a pump system that circulates and replenishes oxygen in the blood. They expect to report more findings as they become available.

"In addition, we have plans to initiate a larger prospective study evaluating delayed, long-term, and chronic neurologic manifestations that may not be known in this early period in the pandemic," Freeman said.

More information

The American Psychological Association has more information on COVID-19's impact on the brain.

SOURCE: Radiological Society of North America, news release, Nov. 18, 2020

Read the rest here:
Diabetes, High Blood Pressure Raise Odds of COVID Harming Brain - HealthDay News

Direct Imaging May Localize Seizure Onset Zone in Patients With Focal Epilepsy – Neurology Advisor

Direct imaging with high-density electroencephalography (EEG) may localize seizure onset zone prior to surgery in patients with focal epilepsy, according to study results published in Neurology.

Identifying the epileptogenic zone is crucial prior to surgical intervention for focal epilepsy and in recent years, EEG has become an important modality to guide surgical interventions. The objective of the current study was to assess the role of EEG recordings and source localization analyses in localizing seizure onset zone prior to surgical planning in patients with focal epilepsy.

The study included 39 adult patients (51.28% women; mean age, 17.87 years) with partial seizures who underwent pre-surgical evaluation with high-density long-term EEG monitoring at Mayo Clinic, Rochester, MN, between 2007 and 2017. Patients underwent either surgical resection or invasive intracranial EEG monitoring. Study researchers used a new method for directly imaging seizure sources and interictal spikes from high density EEGs, and confirmed it for seizure onset zone localization assessed with intracranial EEG findings and surgical resection volume.

There were a total of 138 seizures included in the study. The sub-lobar concordance rate between EEG seizure onset zone results and clinical findings was 94.87%. The difference was more significant in patients with greater than 1 interictal epileptic discharge cluster as ictal source imaging indicated a concordance rate of 87.5%.

The mean localization error, calculated as the average distance from the estimated source to the closest intracranial seizure onset zone electrode, was about 1.35 cm in patients with concordant results. For patients following successful surgery, the average distance from the estimated source to the boundary of the resected volume was 0.74 cm.

The interictal study included at least 10 hours of recordings for each patient. The concordance rate was 78.4% when study researchers used the dominant interictal epileptic discharge cluster for source imaging. The difference was more significant in patients with greater than 1 interictal epileptic discharge cluster as the interictal source imaging showed a concordance rate of 56.2%.

The study had several limitations, including limiting participants to patients with focal epilepsy, the use of high quality magnetic resonance imaging, and the use of high-density EEG.

The present study demonstrates the clinical applicability and merits of a noninvasive electrophysiological seizure imaging approach, which is currently missing in clinical routine, but may become an important component of the pre-surgical evaluation routine for epilepsy treatment, concluded the study researchers.

Reference

Ye S, Yang L, Lu Y, et al. Contribution of ictal source imaging for localizing seizure onset zone in patients with focal epilepsy patients. Neurology. Published online October 23, 2020. doi:10.1212/WNL.0000000000011109

Read the original post:
Direct Imaging May Localize Seizure Onset Zone in Patients With Focal Epilepsy - Neurology Advisor

Society of Vascular and Interventional Neurology Releases Study on Paradigm Shifts in Medical Care During COVID-19 Pandemic – Southernminn.com

MINNEAPOLIS, Nov. 19, 2020 /PRNewswire/ -- The Society of Vascular and Interventional Neurology(SVIN)colleagues andDr. James Siegleridentify that it should come as no surprise that the COVID-19 pandemic and its many "waves" has led to significant paradigm shifts in medical care--from triage all the way to treatment, and SVIN and Dr. Sieglerare releasing a study on Paradigm Shifts in Medical Care During COVID-19Pandemic. Many reports have indicated that patients are avoiding healthcare institutions to prevent contact with COVID-19 patients and healthcare professionals.Falling rates have been observed across a range of acute and critical conditions including myocardial infarction, stroke, and various cancers.The long-term consequences of healthcare avoidance remain unknown but will become clear in the coming months and years.

Using a novel lens to explore these indirect consequences of the COVID-19 pandemic,Dr.Sieglerand colleagues from the Society of Vascular andInterventionalNeurology undertook amulticenterobservational study to evaluate the timeline of critical care that is provided to patients with acute ischemic stroke. These investigators pooled prospectively maintained data from 14 Comprehensive Stroke Centers (CSCs) in nine U.S. states between January 2019 and July 2020.Together, these nine states accounted for nearly half of all COVID-19 cases in the U.S. and more than one-third of all COVID-19-associatedmortalities.(If any indirect effect of the pandemic were to influence the care of stroke patients, it would involve these high-risk geographical regions.) The objective of this investigation was to determine if patients were receiving standard-of-carereperfusiontherapies (e.g., intravenousthrombolysisand/orthrombectomy) with the same expediency during the COVID-19 period as they were in the months prior. Using the AHA Target: Stroke campaign goal of a 60-minute door-to-needle time for intravenousthrombolysisas a primary outcome, the authors found that patients admitted to these hospitals during the COVID-19 pandemic were at a 45% lower odds of being treated in that 60-minute time window (adjusted OR 0.55, 95%CI 0.35-0.85).

The investigators were also able to track the times from patient arrival to firstneuroimagingtothrombolysisbolus. It appears that the principal mediator of the delay inthrombolysiswas the delay in time from head imaging to bolus (median delay of sevenminutes across all sites).Despite the increased need for personal protective equipment, contact precautions, and other barriers between patients and providers, there appeared to be no delay in time from arrival to firstneuroimaging.Furthermore, the delay in care appeared to persist throughout the months of June and July as the second wave of the pandemic spread across the southeastern and western United States.While the overall delay tothrombolysiswas minimal (median delay of only fourminutes), this delay was observed inCSCs, which are known to have faster throughput and treatment times when compared to other healthcare institutions.It is possible that this delay may be magnified in community hospitals, and these findings warrant exploration in non-CSC institutions.

Although there was a mild but significant delay in door-to-needle times during the COVID-19 pandemic, there appeared to be no significant delay in door-to-groin puncture times for patients who underwentendovascularrecanalizationduring COVID-19. This may reflect the careful planning and anticipation of COVID-19 patient care by leaders within the Society of Vascular andInterventionalNeurology, as their consensus guidelines had been published early during the pandemic.

Altogether, these findings suggest large scale gaps in acute medical care for a common neurological problem that affects almost 1 million Americans perannum. It is important for healthcare institutions to appraise their local paradigms in acute stroke care to determine if similar gaps exist, and what steps they can take to reduce delays in care during a global crisis.

About SVIN

The Society of Vascular andInterventionalNeurologyachieves the highest level ofpatient care through collaboration in scientific research and education.The Society provides opportunities to connect leaders in the field and provides a platform for dialogue and creation of practicestandards.Our mission is to advance vascular andinterventionalneurologyto improve clinical outcomes of stroke and cerebrovascular disorders.

For further information about SVIN, visitwww.svin.orgor find us on Facebook, Twitter, orLinkedIn.Media Contact: Jennifer Potter-Vig, PhD |info@svin.org|952-646-2045

Related Images

dr-jim-siegler.jpgDr. Jim SieglerSpeaking on behalf of the Society of Vascular and Interventional Neurology (SVIN) COVID-19 Registry & Task Force at the SVIN Annual Meeting on Thursday, November 19, 2020.

Related Links

SVIN Annual Meeting

See original here:
Society of Vascular and Interventional Neurology Releases Study on Paradigm Shifts in Medical Care During COVID-19 Pandemic - Southernminn.com

Neurological Symptoms Mixed with COVID-19 May Mean Double the Worse Outcomes – DocWire News

Its been documented that patients with preexisting conditions may have greater risks when it comes to COVID-19. Now, according to research, patients with neurological symptoms and COVID-19 may be at risk for not only more severe COVID-19 symptomsbut exacerbated neurological symptoms as well.

The authors of the study queried the MEDLINE and medRxiv databases for relevant studies that reported on patients with preexisting neurological disorders and COVID-19 that reported the severity of the latter and/or changes in symptoms of the former. Severe COVID-19 was defined as having severe/critical pneumonia or admission to the intensive care unit.

Of 1,702 total studies identified (866 from MEDLINE, 836 from medRxiv), 26 studies encompassing 2,278 total patients were included in the final analysis. The disorders represented in the studies included cerebrovascular disease, Parkinsons disease, multiple sclerosis and related disorders, aquaporin-4 (AQP-4)-positive neuromyelitis optica spectrum disorder (NMOSD), dementia and cognitive disorder, epilepsy, spinal cord injury, systemic atrophy, myelopathy, intracranial mass, and unspecified disorders.

Not every study discussed both outcomes (the exacerbation of neurological symptoms and COVID-19 severity), so patients were stratified by those with preexisting neurological disorders and COVID-19 for where exacerbation of neurological symptoms was available (n=232) and where the severe COVID-19 course was available (n=2,618).

Among the patients whose neurological symptoms exacerbation was reported, 74 (31.9%) presented exacerbated preexisting neurological symptoms. This was observed in more than half of the patients with dementia (n=55/92; 59.5%) and Parkinsons disease (n=10/17; 58.8%).

Among the patients whose COVID-19 severity course was reported, 478 (22%) presented worsening COVID-19 severity. This was observed in about one-fifth of patients with cerebrovascular disease (n=86/445; 19.3%) and dementia (n=70/316; 22.2%) and two in five patients with multiple sclerosis (n=28/71; 39.4%); it was also seen in patients Parkinsons disease (25/214; 11.7%), epilepsy (10/98; 10.2%), spinal cord injury (5/7; 71.1%), and unspecified neurological disorders (254/1011; 25%).

The study was published in Clinical Neurology and Neurosurgery.

Clinicians should be aware of the risks of an exacerbation of neurological symptoms and an increase in COVID-19 severity in patients with preexisting neurological diseases, and should focus on the prevention and early care of COVID-19, the researchers concluded.

Read this article:
Neurological Symptoms Mixed with COVID-19 May Mean Double the Worse Outcomes - DocWire News

New NIH BRAIN Initiative awards move toward solving brain disorders – National Institutes of Health

News Release

Thursday, November 19, 2020

Researchers using recently developed tools to gain new insights into brain function.

The National Institutes of Health will fund more than 175 grants, totaling nearly $500 million, through the NIHs Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, part of a large effort among federal and non-federal partners to use knowledge about how the brain works to develop more effective therapies for neurological disorders.

Recent discoveries and new technologies supported by the BRAIN Initiative provide a solid foundation for the next phase of the program, which will focus on large transformative projects and lay the foundation for novel interventions for human brain disorders, said John Ngai, Ph.D., director of the NIH BRAIN Initiative. We are moving closer to a complete list of all of the components in the brain and learning how those parts work together. That knowledge will enable us to develop better treatments for neurologic and neuropsychiatric diseases.

The researchers represent a variety of scientific disciplines from chemistry to engineering to psychology and more.

The new awards include efforts to use deep brain stimulation to enhance sleep in people with Parkinsons disease; explore the neural circuits behind pain; employ ultrasound technology to precisely deliver drugs to the brain; and help people with acute spinal cord injury recover movements and bladder control.

Scientists are also making significant advances in human brain imaging by developing a new type of MRI scanner to watch the brain in action as someone moves; generating ultra-high resolution images of brain chemistry using new PET technology; and using ultrasound to noninvasively map brain electrical activity.

Some grants support integrated research on neuroethical implications of BRAIN-funded neuroscience projects, including issues concerning certain types of neurosurgery and ethical challenges of using mobile neuroimaging technology in field studies.

Meanwhile, others will take a unique approach to studying the brain by developing a range of innovative model systems, beyond traditional fruit flies and rodents. For example, they will study the circuits behind the way an octopus sees and makes decisions; how moths detect harmful stimuli; and the brain connections bats use to navigate in the dark. These studies will provide insights into ways that brain circuitry can affect human behavior.

The BRAIN Initiative started in 2013 as a large-scale effort to accelerate neuroscience research by providing researchers with tools to study and treat human brain disorders. The NIH BRAIN Initiative has focused on brain circuit structure and function as well as the development of technologies to manipulate connections. To date, more than 900 awards totaling approximately $1.8 billion have been supported by the NIH BRAIN Initiative, which is collaboratively managed by 10 institutes.

A number of BRAIN Initiative-supported research findings have been published over the past year including identification of neurons that help rats envision future scenarios; the discovery of specific cells activated by general anesthesia and that may be potential targets for chronic pain treatments; advances in imaging technology that can measure brain activity up to 3,000 times per second in animals; examining nonverbal behavior in people with severe depression who receive deep brain stimulation; watching as odor-sensing cells within the nose react to complex smells; finding brain cells that can initiate torpor, a state of inactivity similar to hibernation; and a new device that may allow real-time control of prosthetic limbs.

For more information, please visit:https://braininitiative.nih.gov/

The NIH BRAIN Initiative is managed by 10 institutes whose missions and current research portfolios complement the goals of the BRAIN Initiative: National Center for Complementary and Integrative Health, National Eye Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Biomedical Imaging and Bioengineering, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute on Drug Abuse, National Institute on Deafness and other Communication Disorders, National Institute of Mental Health, and National Institute of Neurological Disorders and Stroke.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

###

Continued here:
New NIH BRAIN Initiative awards move toward solving brain disorders - National Institutes of Health

Minimally Invasive Neurosurgical Systems Industry to 2030 Rising cases of neurological disorders and growing demand for efficient minimally invasive…

The global minimally invasive neurosurgical systems market size was US$ 467 million in 2021. The global minimally invasive neurosurgical systems market is forecast to grow to US$1,162 million by 2030, growing at a compound annual growth rate (CAGR) of 10.5% during the forecast period from 2022 to 2030.

Request for A Sample Report: https://reportocean.com/industry-verticals/sample-request?report_id=Pol550

The use of minimally invasive neurosurgical systems can be helpful in many ways. It helps surgeons have better visualization than the traditional methods. Moreover, it allows a small incision of the skull during the surgical process.

Factors Influencing

Geographic Overview

North America is forecast to dominate the global minimally invasive neurosurgery system market due to the rapidly rising cases of neurological disorders. Moreover, the increasing penetration of advanced technology and high healthcare expenditure will benefit the global market.

In addition, the rapidly developing healthcare sector and increasing awareness about minimally invasive neurosurgical treatments among the population are forecast to benefit the regional market.

COVID-19 Impact Analysis

Due to the COVID-19 pandemic, the global minimally invasive neurosurgical systems market witnessed an abrupt decline. The authorities and healthcare bodies all around the world were concentrating on curbing the effect of the virus and saving the lives of the people. As a result of this, neurological surgeries were either postponed or canceled for a short period of time. Moreover, patients also stopped visiting hospitals and clinics to prevent themselves from the effect of this deadly virus. Thus, the global minimally invasive neurosurgical systems market witnessed a significant decline.

The global minimally invasive neurosurgical systems market also slowed down due to the unavailability of raw materials, which created various challenges for the market players.

Competitors in the Market

Market Segmentation

The global minimally invasive neurosurgical systems market is segmented on the basis of Product, Surgery Type, and Region.

Insight by Product Type

Insight by Surgery Type

Insight by Region

The global minimally invasive neurosurgical systems market size was US$ 467 million in 2021. The global minimally invasive neurosurgical systems market is forecast to grow to US$1,162 million by 2030, growing at a compound annual growth rate (CAGR) of 10.5% during the forecast period from 2022 to 2030.

The use of minimally invasive neurosurgical systems can be helpful in many ways. It helps surgeons have better visualization than the traditional methods. Moreover, it allows a small incision of the skull during the surgical process.

Factors Influencing

Geographic Overview

North America is forecast to dominate the global minimally invasive neurosurgery system market due to the rapidly rising cases of neurological disorders. Moreover, the increasing penetration of advanced technology and high healthcare expenditure will benefit the global market.

In addition, the rapidly developing healthcare sector and increasing awareness about minimally invasive neurosurgical treatments among the population are forecast to benefit the regional market.

COVID-19 Impact Analysis

Due to the COVID-19 pandemic, the global minimally invasive neurosurgical systems market witnessed an abrupt decline. The authorities and healthcare bodies all around the world were concentrating on curbing the effect of the virus and saving the lives of the people. As a result of this, neurological surgeries were either postponed or canceled for a short period of time. Moreover, patients also stopped visiting hospitals and clinics to prevent themselves from the effect of this deadly virus. Thus, the global minimally invasive neurosurgical systems market witnessed a significant decline.

The global minimally invasive neurosurgical systems market also slowed down due to the unavailability of raw materials, which created various challenges for the market players.

Competitors in the Market

Market Segmentation

The global minimally invasive neurosurgical systems market is segmented on the basis of Product, Surgery Type, and Region.

Insight by Product Type

Insight by Surgery Type

Insight by Region

Download Free Sample Copy of Minimally Invasive Neurosurgical Systems Market@ https://reportocean.com/industry-verticals/sample-request?report_id=Pol550

About Report Ocean:

We are the best market research reports provider in the industry. Report Ocean believe in providing the quality reports to clients to meet the top line and bottom line goals which will boost your market share in todays competitive environment. Report Ocean is one-stop solution for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us:

Report Ocean

Name: Nishi Sharma

Email: sales@reportocean.com

Address: 500 N Michigan Ave, Suite 600, Chicago, IIIinois 60611 UNITED STATES

Tel: +1 888 212 3539 (US TOLL FREE)

Website: https://www.reportocean.com/

Original post:
Minimally Invasive Neurosurgical Systems Industry to 2030 Rising cases of neurological disorders and growing demand for efficient minimally invasive...

Impact Of Covid-19 on Neurology Emr Software Market 2020 Industry Challenges, Business Overview and Forecast Research Study 2026 – PRnews Leader

Overview for Neurology Emr Software Market Helps in providing scope and definitions, Key Findings, Growth Drivers, and Various Dynamics.

The global Neurology Emr Software market focuses on encompassing major statistical evidence for the Neurology Emr Software industry as it offers our readers a value addition on guiding them in encountering the obstacles surrounding the market. A comprehensive addition of several factors such as global distribution, manufacturers, market size, and market factors that affect the global contributions are reported in the study. In addition the Neurology Emr Software study also shifts its attention with an in-depth competitive landscape, defined growth opportunities, market share coupled with product type and applications, key companies responsible for the production, and utilized strategies are also marked.

This intelligence and 2026 forecasts Neurology Emr Software industry report further exhibits a pattern of analyzing previous data sources gathered from reliable sources and sets a precedented growth trajectory for the Neurology Emr Software market. The report also focuses on a comprehensive market revenue streams along with growth patterns, analytics focused on market trends, and the overall volume of the market.

Moreover, the Neurology Emr Software report describes the market division based on various parameters and attributes that are based on geographical distribution, product types, applications, etc. The market segmentation clarifies further regional distribution for the Neurology Emr Software market, business trends, potential revenue sources, and upcoming market opportunities.

Download PDF Sample of Neurology Emr Software Market report @ https://hongchunresearch.com/request-a-sample/53014

Key players in the global Neurology Emr Software market covered in Chapter 4:, Athenahealth, Kareo, Nextgen, Brainlab, Bizmatics, Practice Fusion, Allscripts, NueMD, Advanced Data Systems, Epic, Greenway Health, Healthfusion

In Chapter 11 and 13.3, on the basis of types, the Neurology Emr Software market from 2015 to 2026 is primarily split into:, Advanced Neurology EMR Software, Other

In Chapter 12 and 13.4, on the basis of applications, the Neurology Emr Software market from 2015 to 2026 covers:, Hospitals, College & Research Institutes, Other

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:, North America (Covered in Chapter 6 and 13), United States, Canada, Mexico, Europe (Covered in Chapter 7 and 13), Germany, UK, France, Italy, Spain, Russia, Others, Asia-Pacific (Covered in Chapter 8 and 13), China, Japan, South Korea, Australia, India, Southeast Asia, Others, Middle East and Africa (Covered in Chapter 9 and 13), Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Others, South America (Covered in Chapter 10 and 13), Brazil, Argentina, Columbia, Chile, Others

The Neurology Emr Software market study further highlights the segmentation of the Neurology Emr Software industry on a global distribution. The report focuses on regions of North America, Europe, Asia, and the Rest of the World in terms of developing business trends, preferred market channels, investment feasibility, long term investments, and environmental analysis. The Neurology Emr Software report also calls attention to investigate product capacity, product price, profit streams, supply to demand ratio, production and market growth rate, and a projected growth forecast.

In addition, the Neurology Emr Software market study also covers several factors such as market status, key market trends, growth forecast, and growth opportunities. Furthermore, we analyze the challenges faced by the Neurology Emr Software market in terms of global and regional basis. The study also encompasses a number of opportunities and emerging trends which are considered by considering their impact on the global scale in acquiring a majority of the market share.

The study encompasses a variety of analytical resources such as SWOT analysis and Porters Five Forces analysis coupled with primary and secondary research methodologies. It covers all the bases surrounding the Neurology Emr Software industry as it explores the competitive nature of the market complete with a regional analysis.

Check [emailprotected] https://hongchunresearch.com/check-discount/53014

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Neurology Emr Software Market

Chapter Four: Players Profiles

Chapter Five: Global Neurology Emr Software Market Analysis by Regions

Chapter Six: North America Neurology Emr Software Market Analysis by Countries

Chapter Seven: Europe Neurology Emr Software Market Analysis by Countries

Chapter Eight: Asia-Pacific Neurology Emr Software Market Analysis by Countries

Chapter Nine: Middle East and Africa Neurology Emr Software Market Analysis by Countries

Chapter Ten: South America Neurology Emr Software Market Analysis by Countries

Chapter Eleven: Global Neurology Emr Software Market Segment by Types

Chapter Twelve: Global Neurology Emr Software Market Segment by Applications 12.1 Global Neurology Emr Software Sales, Revenue and Market Share by Applications (2015-2020) 12.1.1 Global Neurology Emr Software Sales and Market Share by Applications (2015-2020) 12.1.2 Global Neurology Emr Software Revenue and Market Share by Applications (2015-2020) 12.2 Hospitals Sales, Revenue and Growth Rate (2015-2020) 12.3 College & Research Institutes Sales, Revenue and Growth Rate (2015-2020) 12.4 Other Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Neurology Emr Software Market Forecast by Regions (2020-2026) continued

List of tablesList of Tables and Figures Table Global Neurology Emr Software Market Size Growth Rate by Type (2020-2026) Figure Global Neurology Emr Software Market Share by Type in 2019 & 2026 Figure Advanced Neurology EMR Software Features Figure Other Features Table Global Neurology Emr Software Market Size Growth by Application (2020-2026) Figure Global Neurology Emr Software Market Share by Application in 2019 & 2026 Figure Hospitals Description Figure College & Research Institutes Description Figure Other Description Figure Global COVID-19 Status Overview Table Influence of COVID-19 Outbreak on Neurology Emr Software Industry Development Table SWOT Analysis Figure Porters Five Forces Analysis Figure Global Neurology Emr Software Market Size and Growth Rate 2015-2026 Table Industry News Table Industry Policies Figure Value Chain Status of Neurology Emr Software Figure Production Process of Neurology Emr Software Figure Manufacturing Cost Structure of Neurology Emr Software Figure Major Company Analysis (by Business Distribution Base, by Product Type) Table Downstream Major Customer Analysis (by Region) Table Athenahealth Profile Table Athenahealth Production, Value, Price, Gross Margin 2015-2020 Table Kareo Profile Table Kareo Production, Value, Price, Gross Margin 2015-2020 Table Nextgen Profile Table Nextgen Production, Value, Price, Gross Margin 2015-2020 Table Brainlab Profile Table Brainlab Production, Value, Price, Gross Margin 2015-2020 Table Bizmatics Profile Table Bizmatics Production, Value, Price, Gross Margin 2015-2020 Table Practice Fusion Profile Table Practice Fusion Production, Value, Price, Gross Margin 2015-2020 Table Allscripts Profile Table Allscripts Production, Value, Price, Gross Margin 2015-2020 Table NueMD Profile Table NueMD Production, Value, Price, Gross Margin 2015-2020 Table Advanced Data Systems Profile Table Advanced Data Systems Production, Value, Price, Gross Margin 2015-2020 Table Epic Profile Table Epic Production, Value, Price, Gross Margin 2015-2020 Table Greenway Health Profile Table Greenway Health Production, Value, Price, Gross Margin 2015-2020 Table Healthfusion Profile Table Healthfusion Production, Value, Price, Gross Margin 2015-2020 Figure Global Neurology Emr Software Sales and Growth Rate (2015-2020) Figure Global Neurology Emr Software Revenue ($) and Growth (2015-2020) Table Global Neurology Emr Software Sales by Regions (2015-2020) Table Global Neurology Emr Software Sales Market Share by Regions (2015-2020) Table Global Neurology Emr Software Revenue ($) by Regions (2015-2020) Table Global Neurology Emr Software Revenue Market Share by Regions (2015-2020) Table Global Neurology Emr Software Revenue Market Share by Regions in 2015 Table Global Neurology Emr Software Revenue Market Share by Regions in 2019 Figure North America Neurology Emr Software Sales and Growth Rate (2015-2020) Figure Europe Neurology Emr Software Sales and Growth Rate (2015-2020) Figure Asia-Pacific Neurology Emr Software Sales and Growth Rate (2015-2020) Figure Middle East and Africa Neurology Emr Software Sales and Growth Rate (2015-2020) Figure South America Neurology Emr Software Sales and Growth Rate (2015-2020) Figure North America Neurology Emr Software Revenue ($) and Growth (2015-2020) Table North America Neurology Emr Software Sales by Countries (2015-2020) Table North America Neurology Emr Software Sales Market Share by Countries (2015-2020) Figure North America Neurology Emr Software Sales Market Share by Countries in 2015 Figure North America Neurology Emr Software Sales Market Share by Countries in 2019 Table North America Neurology Emr Software Revenue ($) by Countries (2015-2020) Table North America Neurology Emr Software Revenue Market Share by Countries (2015-2020) Figure North America Neurology Emr Software Revenue Market Share by Countries in 2015 Figure North America Neurology Emr Software Revenue Market Share by Countries in 2019 Figure United States Neurology Emr Software Sales and Growth Rate (2015-2020) Figure Canada Neurology Emr Software Sales and Growth Rate (2015-2020) Figure Mexico Neurology Emr Software Sales and Growth (2015-2020) Figure Europe Neurology Emr Software Revenue ($) Growth (2015-2020) Table Europe Neurology Emr Software Sales by Countries (2015-2020) Table Europe Neurology Emr Software Sales Market Share by Countries (2015-2020) Figure Europe Neurology Emr Software Sales Market Share by Countries in 2015 Figure Europe Neurology Emr Software Sales Market Share by Countries in 2019 Table Europe Neurology Emr Software Revenue ($) by Countries (2015-2020) Table Europe Neurology Emr Software Revenue Market Share by Countries (2015-2020) Figure Europe Neurology Emr Software Revenue Market Share by Countries in 2015 Figure Europe Neurology Emr Software Revenue Market Share by Countries in 2019 Figure Germany Neurology Emr Software Sales and Growth Rate (2015-2020) Figure UK Neurology Emr Software Sales and Growth Rate (2015-2020) Figure France Neurology Emr Software Sales and Growth Rate (2015-2020) Figure Italy Neurology Emr Software Sales and Growth Rate (2015-2020) Figure Spain Neurology Emr Software Sales and Growth Rate (2015-2020) Figure Russia Neurology Emr Software Sales and Growth Rate (2015-2020) Figure Asia-Pacific Neurology Emr Software Revenue ($) and Growth (2015-2020) Table Asia-Pacific Neurology Emr Software Sales by Countries (2015-2020) Table Asia-Pacific Neurology Emr Software Sales Market Share by Countries (2015-2020) Figure Asia-Pacific Neurology Emr Software Sales Market Share by Countries in 2015 Figure Asia-Pacific Neurology Emr Software Sales Market Share by Countries in 2019 Table Asia-Pacific Neurology Emr Software Revenue ($) by Countries (2015-2020) Table Asia-Pacific Neurology Emr Software Revenue Market Share by Countries (2015-2020) Figure Asia-Pacific Neurology Emr Software Revenue Market Share by Countries in 2015 Figure Asia-Pacific Neurology Emr Software Revenue Market Share by Countries in 2019 Figure China Neurology Emr Software Sales and Growth Rate (2015-2020) Figure Japan Neurology Emr Software Sales and Growth Rate (2015-2020) Figure South Korea Neurology Emr Software Sales and Growth Rate (2015-2020) Figure Australia Neurology Emr Software Sales and Growth Rate (2015-2020) Figure India Neurology Emr Software Sales and Growth Rate (2015-2020) Figure Southeast Asia Neurology Emr Software Sales and Growth Rate (2015-2020) Figure Middle East and Africa Neurology Emr Software Revenue ($) and Growth (2015-2020) continued

About HongChun Research: HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details: Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

Neurology Emr Software :

HongChun Research, Neurology Emr Software , Neurology Emr Software market, Neurology Emr Software industry, Neurology Emr Software market size, Neurology Emr Software market share, Neurology Emr Software market Forecast, Neurology Emr Software market Outlook, Neurology Emr Software market projection, Neurology Emr Software market analysis, Neurology Emr Software market SWOT Analysis, Neurology Emr Software market insights

Read the rest here:
Impact Of Covid-19 on Neurology Emr Software Market 2020 Industry Challenges, Business Overview and Forecast Research Study 2026 - PRnews Leader

COVID-19 Update: Global Neurology EMR Software Market is Expected to Grow at a Healthy CAGR with Top players: NueMD, Greenway Health, AdvancedMD,…

Neurology EMR Software Marketreport analyses the market potential for each geographical region based on the growth rate, macroeconomic parameters, consumer buying patterns, and market demand and supply scenarios. The report covers the present scenario and the growth prospects of the global Neurology EMR Softwaremarket for 2020-2025.

The Neurology EMR SoftwareMarket Report further describes detailed information about tactics and strategies used by leading key companies in the Neurology EMR Softwareindustry. It also gives an extensive study of different market segments and regions.

Request For Exclusive Sample PDF along with few company profileshttps://inforgrowth.com/sample-request/6524466/neurology-emr-software-market

The Top players are

Market Segmentation:

By Product Type:

On the basis of the end users/applications,

HALLOWEEN OFFER: Get up-to 30% Extra Discount for this Exclusive Gene Synthesis Service Market Report, https://inforgrowth.com/discount/6524466/neurology-emr-software-market

Impact of COVID-19:

Neurology EMR Software Market report analyses the impact of Coronavirus (COVID-19) on the Neurology EMR Software industry. Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 180+ countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Neurology EMR Software market in 2020.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; emergency declared in many countries; massive slowing of the supply chain; stock market unpredictability; falling business assurance, growing panic among the population, and uncertainty about future.

COVID-19 can affect the global economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets.

Get Sample ToC to understand the CORONA Virus/COVID19 impact and be smart in redefining business strategies. https://inforgrowth.com/CovidImpact-Request/6524466/neurology-emr-software-market

Reasons to Get this Report:

Study on Table of Contents:

ENQUIRE MORE ABOUT THIS REPORT AT https://inforgrowth.com/enquiry/6524466/neurology-emr-software-market

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: +1-909-329-2808UK: +44 (203) 743 1898Website:

Read the original here:
COVID-19 Update: Global Neurology EMR Software Market is Expected to Grow at a Healthy CAGR with Top players: NueMD, Greenway Health, AdvancedMD,...

Overweight/Obesity in Young Adulthood Linked to Increased Risk of MS – Neurology Advisor

Overweight/obese levels of BMI at age 20, paired with history of infectious mononucleosis (IM) or high Epstein-Barr nuclear antigen 1 (EBNA-1) antibody levels, synergize in elevating the risk of multiple sclerosis (MS), and the effect strengthens with increasing antibody levels, according to study results published in Neurology: Neuroimmunology & Neuroinflammation. Results also indicated significant 3-way additive interactions between DRB1*15:01 allele, BMI at age 20 years, and each aspect of Epstein Barr virus (EBV) infection.

The study researchers sought to find out whether these MS risk factors had an additive interaction for the inflammatory disease, and to analyze 3-way interactions between BMI at age 20, EBV infection, and the human leukocyte antigen (HLA)-DRB1* 15:01 allele.

They used data from the Epidemiological Investigation of Multiple Sclerosis (EIMS) and Genes and Environment in Multiple Sclerosis (GEMS) studies, 2 Swedish population-based case-control studies on environmental and genetic risk factors for MS. In the former, newly diagnosed cases of MS were recruited from neurology clinics and matched with 2 randomly selected controls from the countrys national population register, frequency matched in 5-year age strata, sex, and residential area. GEMS presented prevalent cases of MS from the Swedish National MS Registry, each of whom was matched with 1 control in the same way as in EIMS.

The study researchers also included controls from the Epidemiological Investigation of Rheumatoid Arthritis, which was designed in the same manner and with a similar study population as EIMS. Participants provided blood samples for the genotyping and self-reported contraction of IM, body height, and weight.

The combination of two risk factors, overweight/obesity at age 20 years and a history of IM, synergistically increased the risk of MS 5-fold. In contrast, nonoverweight subjects with IM history had a 90% increased risk of MS and those with overweight/obesity at age 20 years (BMI I 25 kg/m2) without IM history had a 40% increased MS risk.

BMI at age 20 years and high EBNA-1 antibody levels, even without history of IM, had a similar interaction that increased with elevated EBNA-1 antibody levels.

2-way interactions were present between DRB1*15:01 and overweight/obesity at age 20 years, between DRB1*15:01 and each aspect of EBV infection, and between overweight/obesity at age 20 years and each aspect of EBV infection. DRB1*15:01, BMI at age 20 years, and each aspect of EBV infection (IM history and high EBNA-1 antibody levels, respectively) had significant 3-way interactions.

These findings held significant for both EIMS and GEMS when investigators restricted the analysis to subjects with complete data on HLA alleles and EBNA-1 antibody levels.

Limitations of the study included selection bias and recall bias in the studies and risk of misclassification when dichotomizing subjects into those with and without self-reported IM history.

The study researchers concluded, The obese state both induces a chronic immune-mediated inflammation and affects the cellular immune response to infections, which may contribute to explain our findings. They added that their data reinforce the importance of intervention efforts against childhood and adolescent obesity to reduce MS incidence.

Disclosure: Several authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors disclosures.

Reference

Hedstrm AK, Brenner N, Butt J, et al. Overweight/obesity in young adulthood interacts with aspects of EBV infection in MS etiology. Neurol Neuroimmunol Neuroinflamm. Published online December 15, 2020. doi:10.1212/NXI.0000000000000912

Read the rest here:
Overweight/Obesity in Young Adulthood Linked to Increased Risk of MS - Neurology Advisor

20 Years Later, The Pressures and Opportunities Facing… : Neurology Today – LWW Journals

Article In Brief

The loss of protected time for research and a focus on clinical revenue and relative value units has changed the traditional balance of academic neurology from the traditional triad of research, teaching, and clinical practice. But some of the changes in the last 20 years are for the better, academic neurology chairs told Neurology Today.

With great advances comes greater pressure to deliver clinical care to patients.

Twenty-one years into the 21st century, neurology chairs across the United States say that academic medicine has seen vast changesmany of them exciting, some not so much.

On the plus side, new discoveries and treatments offer neurologists new tools and subspecialties to treat more patients.

When I was a student and resident, I would hear people say, Neurology is diagnose and adios, said Matthew Rizzo, MD, FAAN, professor and chair of the department of neurological sciences at the University of Nebraska. It's not that at all now. So many treatments are available for the acute and chronic diseases we treat. And there are more and more people who seek neurologic care. What I see is opportunity upon opportunity.

At the same time, he and four other chairs who spoke to Neurology Today agreed, demands on academic neurologists to spend more time treating patients and less time on research and teaching have led to increased stress and, for some, burnout.

The emphasis on high throughput has definitely hurt academic neurology, said Clifton Gooch, MD, FAAN, professor and chair of neurology at the University of South Florida's (USF) Morsani College of Medicine. Neurology has more complicated patients than most other areas of medicine to begin with, and the most challenging patients from within this group are referred to academic neurology departments. So when some health systems say, We want you to spend 30 minutes on a new patient with severe Alzheimer's disease and 15 minutes to follow up a complex Parkinson's disease patient, you simply can't provide adequate care, and that puts you under tremendous stress. Department leadership is critical to mitigate demands such as these on faculty, but it can be challenging.

On balance, though, all five chairs said the positives in today's academic neurology far outweigh the negatives.

I finished my fellowship in 1987, when there was more protected time for research and teaching, said Kathleen M. Shannon, MD, FAAN, FANA, professor and chair of neurology at the University of Wisconsin School of Medicine and Public Health. Since then, she said, The pressure for patient care has really, really gone up. That has led to a lot of burnout issues. But don't get me wrong. Academic neurology is a wonderful place. It still attracts the very best people, who are 100 percent committed to taking care of their patients and making their lives better. I really love what I do. It's just hard to know the struggles that my folks are facing.

To help neurologists in every career path better handle the challenges of practicing in an academic setting, the AAN established an Academic Neurology Initiative under its past president, Ralph L. Sacco, MD, FAAN, FAHA, professor and chair of neurology at the University of Miami Leonard Miller School of Medicine.

Many people went into academic medicine to do research and teaching, but the clinical mission is growing more rapidly, Dr. Sacco said. The revenue for academic health systems is much more dependent now on clinical revenues. The AAN felt strongly there was more help needed for neurologists in academic medical centers to deal with the new realities.

Back in the day, Dr. Rizzo said, Neurology departments were basically fiefdoms. Department chairs had a lot of power and leverage over the way money got spent, how the clinic was organized. What I've seen over the course of my career is the corporatization of medicine. You have C-suites and CFOs and CEOs. When I started out, all we had were doctors, nurses, ward clerks, and patients. It was pretty simple.

Dr. Gooch, who in 2017 published a survey of academic neurology departments, described the last couple of decades of the 20th century as a fiscal golden age for neurologists and other physicians.

There was a lot more money in medicine at that time, he said. The baby boomers were younger and healthier, working and paying into the health insurance system while consuming fewer services and clinical reimbursement was good. States provided a much greater portion of most medical school budgets. There was funded time to teach and do research, including small exploratory and/or descriptive clinical research projects. The clinical productivity metric of RVUs [relative value units] were first introduced in 1989, and were not yet an unyielding standard of performance .

Changes accelerated with the advent of managed care, Dr. Gooch said. As we approached the year 2000, the baby boomers started retiring and began consuming health care rather than working and paying into the system. This and other factors, including the development of more expensive technologies and treatments, contributed to rising health care costs, causing Medicare and businesses to look for ways to rein in expenses. Consequently, managed care was born, with a major focus on cutting reimbursement for clinical services, he said. At the same time, state support fell. When I became chair here at USF in 2008, 40 percent of the medical school's budget was from the state. Now it's below 10 percent and continues to fall.

Steven Galetta, MD, FAAN, professor and chair of neurology at NYU Grossman School of Medicine, said that back in the 1990s, Most of us were doing general neurology. As the decade progressed, subspecialty fellowships emerged, particularly for stroke and neurocritical care. We started off with no headache medicine specialists. Now we have six.

As more medicines became available for headaches, multiple sclerosis, stroke, and other disorders, the demand for neurological care became tremendous, Dr. Galetta said. As NYU has taken over smaller health systems in nearby Brooklyn and Long island, he said, We went from seeing 7,000 outpatients in 2012 to nearly 100,000 this year. We've hired over a hundred neurologists in those years.

Even as total US spending on health care has grown vastly in the 21st century, reaching $3.8 trillion in 2019amounting to 17.7 percent of the nation's gross domestic productthe portion going to academic neurologists has hardly kept pace.

The pie has gotten bigger, Dr. Gooch said, but pharma is consuming a much bigger percentage of the pie, and the insurance industry is taking its cut too.

Another irony in the evolution of academic medicine is that while the total amount of research money available from the National Institutes of Health (NIH) has grown, getting an NIH grant for a clinical trial has become increasingly difficult.

While the NIH is the major source of funding for critical basic biomedical researchmouse models of disease, cell cultures, etc., only a very small percentage of the NIH budget is dedicated to human clinical trials, which are very expensive, Dr. Gooch said.

In the past, much of this work, especially exploratory therapeutic studies in humans, was funded by excess clinical revenues, which dried up in the late 90s, Dr. Gooch said. This means a lot of this very important early phase clinical research has been pared back. At the same time, NIH-funded basic research has become the coin of the realm in most academic centers, with broad influence on metrics such as the US News medical school rankings.

As with so many other workers in the 21st century, academic neurologists are now gauged by measures of their productivity.

In the old days, you got a salary and you did your workclinical, teaching, research, and administration, Dr. Sacco said. Now each component is measured. And the measure of clinical productivity is by RVUs. When a clinician sees a patient, or reads an EEG or EMG, they generate a certain amount of RVUs. It's become more metrics-driven. If you're not making your clinical RVUs, your salary could be reduced or you might have to do more clinical time to support your salary.

Despite all the pressures, Dr. Rizzo said, It's crazy to be negative. We have so much opportunity. More and more people need neurological care.

That optimistic view was echoed by Frances E. Jensen, MD, FAAN professor and chair of neurology at the University of Pennsylvania's Perelman School of Medicine.

Academic neurology is in an incredibly dynamic state right now, she said. I am unbelievably excited. I pinch myself every day that I'm actually in the field I'm in. We are moving ahead at a pace that is unprecedented for our field. Twenty-five years ago, neurology was more of a watch and wait and document field. What's happening now, because so many treatments are translating to direct patient care, is we're seeing new opportunities and career paths emerge. We're seeing interactions with industry. There are people looking at population-based studies, public health, operations, safety, and quality.

That's not to say it's all gumdrops and unicorns. Yes, of course, my faculty have to mind their RVUs, Dr. Jensen said. But we also focus on having them participate at the top of their licensure. If you continually ask people to work below their licensure, it becomes demoralizing for them, and you are not tapping their potential for program growth. So we work hard to think about how to use physician assistants and advanced practice nurses. The documentation required in electronic medical records is not going to go away. The question is: How do we automate or find other professionals to handle some of it? We have to be adaptive.

Dr. Gooch said he sees hope for reducing the pressure on academic neurologists to see ever more patients in less time is by moving away from a fee-for-service model.

The movement to population health management changes the whole paradigm, he said. It means each health system gets a set amount of money each year to treat a defined population in their area. So the game becomes here's the money, this is it, use it wisely. Now you want to do fewer expensive procedures. You want to invest in internists, neurologists, and family practitioners to keep your population healthy so that they don't need surgery or emergency medical care. In this model, which is more logical, cost effective, and most importantly, better for the patient, the value of clinical neurology will soar, along with the other cognitive specialties.

The move to population health management is already well underway and is a major strategy of the Affordable Care Act in the form of Accountable Care Organizations ( ACOs). Existing large health maintenance organizationtype health systems are best positioned to transition to the ACO model, and many academic medical centers are actively expanding to enter this space.

For all the changes that have affected academic neurology in the past 20 years and will continue to do so, Dr. Rizzo said, What hasn't changed is the neurologist's diligence, aptitude, and appetite for solving really hard clinical problems and digging into the science to find cures. Neurologists remain a very special group of people.

Dr. Sacco said he, too, remains optimistic. With every challenge comes a new opportunity, he said. We will remain resilient and work collectively together to chart a new course forward.

None of the sources quoted in this stories had conflicts of interest to report.

Read the rest here:
20 Years Later, The Pressures and Opportunities Facing... : Neurology Today - LWW Journals

Hutch Clinic welcomes new physicians in Neurology and OB/GYN – The Hutchinson News

By The News staff| The Hutchinson News

Hutchinson Clinic announced the addition of two doctors to its roster of physicians Drs. Rizwan Hassan and Jessica Poteet.

Dr. Hassan comes to Hutchinson from Wichita, where he has more than 40 years of experience diagnosing and treating neurological conditions ranging from epilepsy, Parkinsons, dementia, multiple sclerosis, and stroke.

Most recently, he worked with the Neurology Associates of Kansas to conduct neurological testing and procedures.

In neurology, a specialty that affects all systems of the body, Dr. Hassan approaches patient care with a long-term relationship in mind, acting with compassion and collaborating with other specialists to determine his patients best care path forward.

Dr. Poteet, a graduate of Oklahoma State University College of Osteopathic Medicine, comes to Hutchinson from Utica Park Clinic of Owasso, Oklahoma. She also served as Chief of Surgery for Bailey Medical Center and previously as Chief Resident for St. Anthony Hospital.

Dr. Poteet aims to be a health partner to the women she serves.

She takes a creative and personalized approach to care, assessing the wants and needs of her patients to find solutions that they are comfortable with and to support them during big life moments.

Hutchinson Clinic is expanding access to high-quality care in 2021 with the addition of these two new physicians to our leading clinical team, said Mike Heck, CEO of Hutchinson Clinic.

Dr. Rizwan Hassan will offer new expertise to our patients and play a vital role in building our neurology services," he said. "Our OB/GYN team continues to grow, serving mothers, women, and families in our community, with the addition of Dr. Jessica Poteet. They are both excellent providers who share in our mission and passion for serving the community.

Both are accepting new patients. Call (620) 669-2500 or visit HutchClinic.com to schedule a visit.

Read more here:
Hutch Clinic welcomes new physicians in Neurology and OB/GYN - The Hutchinson News